Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 102.41M P/E - EPS this Y 54.70% Ern Qtrly Grth -
Income -48.41M Forward P/E -1.83 EPS next Y -36.50% 50D Avg Chg -12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book 2.44 EPS next 5Y - 52W High Chg -69.00%
Recommedations 2.20 Quick Ratio 18.67 Shares Outstanding 53.27M 52W Low Chg 12.00%
Insider Own 0.69% ROA -33.09% Shares Float 52.79M Beta 1.72
Inst Own 56.92% ROE -133.75% Shares Shorted/Prior 450.02K/378.72K Price 3.07
Gross Margin - Profit Margin - Avg. Volume 108,772 Target Price 10.25
Oper. Margin - Earnings Date Nov 11 Volume 31,559 Change -3.15%
About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc. News
11/12/24 Milestone Pharmaceuticals: Q3 Earnings Snapshot
11/12/24 Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
10/09/24 Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%
09/24/24 Milestone Pharmaceuticals to Host Investor KOL Event
09/06/24 Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
09/04/24 Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
09/03/24 Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/26/24 Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
08/08/24 Milestone Pharmaceuticals: Q2 Earnings Snapshot
08/08/24 Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
07/31/24 Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference
07/15/24 Milestone Pharmaceuticals Refreshes Board of Directors
06/12/24 Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024
06/07/24 It Looks Like Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO May Expect Their Salary To Be Put Under The Microscope
05/31/24 Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
05/29/24 Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
05/22/24 Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
05/16/24 Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
05/13/24 Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
05/02/24 Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
MIST Chatroom

User Image Stockstunks Posted - 1 day ago

$SHIB.X this shit ain’t going anywhere better of to invest money on $mist

User Image Stockstunks Posted - 1 day ago

$SHIB.X don’t miss the ride $mist

User Image AnalRetort Posted - 2 days ago

$MIST I'm long here and all things considered with xbi on fire this has held up reasonably well. More importantly Joseph's hair - is this like a Canadian thing or something?

User Image Stocktherock Posted - 2 days ago

@Yuvyuv If $MIST gets FDA approval, what’s your realistic sp prediction??

User Image Yuvyuv Posted - 2 days ago

$MIST On the day of approval they will receive $75m from the non dilutive royalty agreement. That means that in total they’ll have approximately $135m in cash and cash equivalents. So: 1. $135m in cash 2. FDA approved drug for PSVT that has potential revenues of up to $1B 3. Successful phase 3 for PSVT trial in China 4. Initiation of phase 3 study in AFib-RVR And the current market cap is $90m Just wait.

User Image DebWater_ Posted - 2 days ago

$MIST Brutal Day today.

User Image Rroper Posted - 2 days ago

$MIST Buying all the way down in .10 cent increments. Load while you can. Wont last long. Coiling.

User Image Shawhwk Posted - 3 days ago

$MIST Very low volume today. I think panic selling took place yesterday. Holding strong with 15k shares.

User Image 14kmaker Posted - 3 days ago

$MIST In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report), with a price target of $25.00

User Image Trash_Man Posted - 3 days ago

$MIST finally hit my target share count of 20K. I am ready for 2025!!

User Image Rroper Posted - 3 days ago

$MIST Anything below 2 is golden here. Cheaper the better. Is coming. I can see the momentum building. 3-4 after new year.

User Image sorcefm Posted - 3 days ago

$PEPE.X don’t sleep on $MIST

User Image DebWater_ Posted - 3 days ago

$MIST closed 3 red for the last 3 days. It is time for a Great Green Day!! 🙏❤️😄

User Image DebWater_ Posted - 4 days ago

$MIST Do you believe? https://www.tipranks.com/stocks/mist/forecast

User Image 14kmaker Posted - 4 days ago

$MIST Milestone Pharmaceuticals (MIST) Gets a Buy from Piper Sandler

User Image 14kmaker Posted - 4 days ago

$MIST just about back where it started today, maybe we finish green …

User Image Yuvyuv Posted - 4 days ago

$MIST

User Image Rroper Posted - 4 days ago

$MIST Nice my fill order hit at 1.67. Loaded a big pile. Love this play. ATM here we come.

User Image buymoremakemore Posted - 4 days ago

$MIST price already recovering

User Image Yuvyuv Posted - 4 days ago

$MIST S-3 filings cover a period of three years. As noted on their website, the previous S-3 filing occurred exactly three years ago, in November 2021, and specified the same amount—$250 million. There's no cause for concern; they simply needed to renew it. Best of luck!

User Image dee64 Posted - 4 days ago

@Takeiteasy30 I sold my small position yesterday. I will keep $MIST on my radar as the company gets closer to its PDUFA date.

User Image Takeiteasy30 Posted - 4 days ago

$MIST I sold on their pump few days ago but i am not bearish here. I just leave it what i posted month ago and some people were arguing with me that no way its gonna happen. If they lied once you never trust them or at least you are cautious with their action. It might be great in long term but that would be on expense of shareholder value (thats only my opinion)

User Image 14kmaker Posted - 4 days ago

$MIST smart money knows that today is a buying day. Because today it’s mixed shelf offering news. Tomorrow or sometime soon institutional investors have to report their increased positions in MIST. Believe me, this is set to gap higher.

User Image HarveySpecter20 Posted - 4 days ago

$MIST added more

User Image PsychTrades Posted - 4 days ago

$MIST averaging down this morning after my ill-timed starter yesterday 😂. I’m okay with the offering coming now, as it gives a clear runway to PDUFA

User Image AnalRetort Posted - 4 days ago

$MIST it should come as no surprise that the cash on hand is not enough to fund a massive phase 3 for AFib and hire and launch a sales staff. Hopefully they time it right for minimum pain, generally right after pdufa would be the best point imo.

User Image DebWater_ Posted - 4 days ago

$MIST This sec 3 filing about an offering did not state when they will actually use it. They have years do use it. They have enough cash right now so there is no need to do an offering immediately. It looks like a lot of assumptions are taking place when nothing actually happened as of now.

User Image Hn1989 Posted - 4 days ago

$MIST Hey, I get it—$250M offering sounds big, and sure, there might be a short-term dip. But let’s zoom out for a sec. They’ve got an FDA decision coming up in March 2025 for a new drug, which could be a massive win if it goes through. Remember CAPR just a month ago? They did an offering too, and yeah, the price dipped at first. But it didn’t take long for them to bounce back and even trade higher. If $MIST is using this cash right—for R&D, scaling up, or getting ready for the big FDA call—this could be a solid setup for long-term holders. Biotech stocks are a rollercoaster, but sometimes patience pays off. Just saying!

User Image vaselineguy Posted - 4 days ago

$MIST good call for q1 2025

User Image Yuvyuv Posted - 4 days ago

$MIST I’m not bothered by this filling. 1. Most likely they will raise post approval in a good price per share. 2. Even if they raise $30m or more before the PDUFA, it means they’ll have more than $100m in cash. It makes the company even MORE desirable as we approach the PDUFA date. It might drop because of this filling and the fear of dilution, but it will quickly recover.

Analyst Ratings
HC Wainwright & Co. Buy Aug 22, 24
Rodman & Renshaw Buy Aug 22, 24
HC Wainwright & Co. Buy Jul 1, 24
HC Wainwright & Co. Buy May 30, 24
HC Wainwright & Co. Buy May 16, 24
HC Wainwright & Co. Buy Mar 22, 24
Piper Sandler Overweight Mar 5, 24
HC Wainwright & Co. Buy Feb 26, 24
TD Cowen Outperform Dec 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wills Robert James Director Director Oct 19 Buy 4.93 15,000 73,950 15,000 10/21/22
Pasternak Richard C Director Director Oct 20 Buy 5.20 10,000 52,000 10,000 10/21/22
Liebert Debra K. Director Director Oct 20 Buy 5.28 14,000 73,920 4,000 10/21/22
TOMSICEK MICHAEL JOHN Director Director Oct 19 Buy 5.32 15,000 79,800 15,000 10/21/22
RTW INVESTMENTS, LP 10% Owner 10% Owner Sep 07 Buy 8.71 1,557,346 13,564,484 4,315,102 09/09/22
RTW INVESTMENTS, LP 10% Owner 10% Owner Sep 07 Sell 8.71 1,557,346 13,564,484 4,315,102 09/09/22
TRUEX PAUL F Director Director May 31 Option 1.72 76,780 132,062 76,780 06/01/22
TRUEX PAUL F Director Director May 31 Buy 5.6 5,000 28,000 81,780 06/01/22